LEXX
Lexaria Bioscience Corp.
There isn't enough reported data to score LEXX yet.
LEXX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Under pressure | |
| Unavailable |
LEXX's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LEXX PE Valuation
LEXX has no meaningful PE right now: it lost money over the past year.
LEXX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect LEXX's losses to grow, with revenue holding steady.
LEXX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$5.25 | +$5.46 |
| Q1 2026 | -$7.20 | +$2.05 |
| Q4 2025 | -$8.55 | -$0.80 |
| Q3 2025 | -$9.90 | -$2.85 |
| Q2 2025 | -$10.71 | -$4.77 |
| Q1 2025 | -$9.25 | -$0.60 |
| Q4 2024 | -$7.75 | +$3.39 |
| Q3 2024 | -$7.05 | +$6.83 |
LEXX is still losing money, but far less than before: $5.25 per share over the past year, against $27.00 at its worst in mid-2020.
LEXX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $20K | -89% |
| Q3 2025 | $174K | +107% |
| Q2 2025 | $174K | +107% |
| Q1 2025 | $174K | +20% |
| Q4 2024 | $183.9K | +22% |
| Q2 2024 | $84K | -9.8% |
| Q1 2024 | $145K | +314% |
| Q4 2023 | $151.3K | +49% |
LEXX's revenue has slid since its 2020 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -7260% | -5679 points |
| Q3 2025 | -1545% | +1078 points |
| Q2 2025 | -2155% | -81 points |
| Q1 2025 | -1581% | -1120 points |
| Q4 2024 | -1463% | -710 points |
| Q3 2024 | -2623% | N/A |
| Q2 2024 | -2075% | N/A |
| Q1 2024 | -461% | N/A |
LEXX's operating margin was −7260% last quarter, down 5797 points from the same quarter a year ago, near the bottom of its range since 2022.
LEXX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.6M | +$1.9M |
| Q1 2026 | -$2.2M | -$706.8K |
| Q4 2025 | -$984.1K | +$1.8M |
| Q3 2025 | -$2.6M | -$707.8K |
| Q2 2025 | -$3.6M | -$2.3M |
| Q1 2025 | -$1.5M | -$878.3K |
| Q4 2024 | -$2.8M | -$1.6M |
| Q3 2024 | -$1.9M | -$244.6K |
LEXX has burned cash in almost every quarter: −$7M over the past year, against −$10M the year before.
LEXX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +24.1K shares |
| 1 year | +36% | +434K shares |
| 3 years | +314% | +1.3M shares |
| 5 years | +726% | +1.5M shares |
| Available history | +857% | +1.5M shares |
LEXX has 2M diluted shares, up 36% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2023 | — |
LEXX Net Leverage
LEXX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LEXX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.6 | Neutral |
| Stochastic | 13.6 | Oversold |
LEXX's weekly RSI is 43 (neutral) and its Stochastic is 14 (oversold).
LEXX PE vs Healthcare Sector
LEXX has no meaningful PE right now: it lost money over the past year.
LEXX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.45 | 21% above |
| 20 week MA | $6.32 | 34% below |
| 50 week MA | $9.25 | 55% below |
| 100 week MA | $14.0 | 70% below |
| 200 week MA | $23.3 | 82% below |
LEXX has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 82% below its 200-week average.
LEXX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $68.7 | $62.9 | -8.5% |
| 2022 | $62.9 | $36.8 | -42% |
| 2023 | $36.8 | $18.8 | -49% |
| 2024 | $18.8 | $34.4 | +83% |
| 2025 | $34.4 | $7.96 | -77% |
| 2026 YTD | $7.96 | $4.18 | -47% |
LEXX has finished lower in four of the last five years. It's down 47% so far in 2026.